Extracellular vesicles from thapsigargin‐treated mesenchymal stem cells ameliorated experimental colitis via enhanced immunomodulatory properties

Abstract

Therapeutic applications of extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) have attracted considerable attention because of their immunomodulatory properties against immune‐mediated, inflammatory diseases. Here, we demonstrated enhanced immunomodulatory properties of EVs secreted from endoplasmic reticulum (ER) stress inducer thapsigargin (TSG)‐primed human Wharton’s jelly‐derived MSCs (WJ‐MSCs). EVs from TSG‐primed WJ‐MSCs (TSG‐EV) showed increased yield and expression of immunomodulatory factors, such as transforming growth factor‐β1 (TGFβ), cyclooxygenase‐2 (COX2), and especially indoleamine 2,3‐dioxygenase (IDO), compared to control EVs. TSG‐EV showed a significantly enhanced immunosuppressive effect on human peripheral blood‐derived T cell proliferation and Th1 and Th17 differentiation, whereas Treg and M2‐type macrophage were enriched compared to a control EV‐treated group. Furthermore, TSG‐EV substantially mitigated mouse experimental colitis by reducing the inflammatory response and maintaining intestinal barrier integrity. A significant increase of Tregs and M2‐type macrophages in colitic colons of a TSG‐EV‐treated mouse suggests an anti‐inflammatory effect of TSG‐EV in colitis model, possibly mediated by Treg and macrophage polarization. These data indicate that TSG treatment promoted immunomodulatory properties of EVs from WJ‐MSCs, and TSG‐EV may provide a new therapeutic approach for treatment of colitis.